Welcome to another episode with the DNB//Back Bay Partnership for Healthcare.
In this episode Jonathan Gertler, Back Bay CEO and Managing Partner, is once again joined by James Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director of US Equity Capital Markets at DNB, and Vasilios Kofitsas, Managing Director of Investment Banking at Back Bay Life Science Advisors, to talk about current market dynamics and the 2024 IPO outlook in the US and in Europe.
Topics in this podcast include:
- Trends, cycles and the current state of capital markets in Europe and the US
- IPO performance for Q1 2024 vs. previous years
- Top characteristics of companies well-suited to go public and be successful
- IPO market dynamics in Europe vs. the US
- Expectations and advice for companies contemplating going public
As always we welcome listener questions and/or topics you’d like to learn more about.
You can listen to previous episodes
here or submit your inquiries to info@bblsa.com.
Learn more about the DNB//Back Bay Partnership and read our disclaimers at
https://www.bblsa.com/dnb-back-bay-partnership.
What is Back Bay Life Science Report?
Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, strategic, and financial analysis at the intersection of science and business.